Your browser doesn't support javascript.
loading
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen, Inna M; Donia, Marco; Chamberlain, Christopher A; Jensen, Agnete W P; Draghi, Arianna; Theile, Susann; Madsen, Kasper; Hasselby, Jane P; Toxværd, Anders; Høgdall, Estrid; Lorentzen, Torben; Wilken, Eva E; Geertsen, Poul; Svane, Inge M; Johansen, Julia S; Nielsen, Dorte.
Afiliação
  • Chen IM; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark. Electronic address: Inna.Chen@regionh.dk.
  • Donia M; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University
  • Chamberlain CA; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Jensen AWP; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Draghi A; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Theile S; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Madsen K; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Hasselby JP; Department of Pathology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Toxværd A; Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Høgdall E; Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Lorentzen T; Department of Gastroenterology, Unit of Surgical Ultrasound, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Wilken EE; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Geertsen P; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Svane IM; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University
  • Johansen JS; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen Univ
  • Nielsen D; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.
Eur J Cancer ; 180: 125-133, 2023 02.
Article em En | MEDLINE | ID: mdl-36592507
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Radiocirurgia Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Radiocirurgia Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article